WCG is the world's leading strategic partner to sponsors, CROs, institutions, and sites providing agile, knowledge based services that proactively optimize clinical development programs. For more information, visit www.wcgclinical.com.
WCG’s end-to-end patient recruitment solution connects patients to clinical trials, enhances site resources and capabilities, and improves study data quality and endpoints. On average, we are helping our clients achieve a 33% acceleration in their enrollment timelines.
The right sites can make all the difference. At WCG, we help clients to identify, select, and engage the highest performing investigators for their clinical research trials.
For 50 years, WIRB-Copernicus Group has stood as the gold standard of ethical and regulatory human research oversight, with more years of IRB and IBC experience and more deep, trusted relationships with sponsors, CROs, institutions, and investigators.
WCG offers the only global safety reporting solution and PV services that have been demonstrated to increase compliance and improve patient safety, while reducing cost and streamlining operations.
WCG
212 Carnegie Center
Princeton, NJ 08540
UNITED STATES
Phone: 609-945-0120
Contact: Lauren Ozmore
Studies show that most clinical trial participants want to know what was learned from their involvement. A growing number of sponsors are implementing plans to deliver plain language summaries to trial participants. Read this white paper to learn about the current best practices for the content and preparation of plain language summaries, and the current guidance for how sponsors should work with Institutional Review Boards (IRBs) which have oversight of the clinical trials for which the summaries are provided.
In recent years, alongside the increase in patient involvement in the design and conduct of research programs, there has been a notable increase in the idea of “virtual” or “decentralized” clinical trials. This paper examines the nature of virtual clinical trials, potential benefits and risks of this new paradigm, and best practices for maintaining regulatory and Institutional Review Board (IRB) compliance.
Recruitment practices for clinical trials have evolved significantly over the last few decades. Read this white paper to learn about the evolution of acceptable recruitment practices, and what IRB members typically look for when reviewing recruitment materials and practices.
Well-performed site feasibility can become the single most important factor in reducing costs and time spent in a clinical trial. With adoption of benchmarking and clinical trial tools, sponsors are able to know exactly how many sites they need in their trial, which makes site pre-identification essential for efficient study start-up.
Nearly 80% of clinical trials fail to meet their activation timelines. But why does the start-up process fail us this often? This question can be answered by implementing a Feasibility Maturity Model with six critical variables: data, process, technology, expertise, focus, and engagement.
In a clinical trial, so much depends on contract execution and budget development; when they are not appropriately managed, progress across other study start up areas comes to a halt. Valuable time is waster, which costs dearly. By implementing three successful approaches to a new way of conducting contracting and budgeting, sponsors and CROs can see a 37% faster site contract execution timeline.
In this on-demand webcast, WCG experts Dr. Nathaniel Katz and Dr. Mark Opler illustrate why human error—including inaccurate symptom reporting—is driving placebo response and how proven, evidence-based interventions can be used to increase the overall chance of trial success. Hear their perspectives.
Every person participating in a clinical trial creates inherent variability in the way they perform. A patient’s ability to report their symptoms accurately will impact trial data, as will a site staff’s verbal and non-verbal communication cues. But what if you could train people to reduce measurement error—and even decrease the placebo response? Read the article to find out how.
The WIRB-Copernicus Group®’s (WCG™) Clinical Services Division introduces Velos eResearch eXpress™, an out-of-the-box, cloud-based solution that enables clinical research sites to centralize and manage their research activities on a single, automated technology platform.
This article provides practical solutions for overcoming the biggest challenges independent clinical research sites face in data collection. Further, it highlights three key metrics that will help sites improve performance and drive success.
The placebo effect. It’s the curse of clinical trials across indications, but it’s a particularly thorny issue for pain researchers. In fact, along with the inability of many patients to accurately report symptoms, it may be the main challenge facing analgesic trials. Left unaddressed, these issues have contributed to the failure of many clinical trials.
In this blog post we discuss how central surveillance using statistical process control (SPC) and other analytical techniques-- combined with expert human analysis--maximizes assay and endpoint sensitivity, allowing sponsors to meet scientific and regulatory expectations for quality data in clinical trials.
Recruitment is one of the things sites and sponsors just do. Everyone thinks they know what it means. But it’s so much more complicated than they imagine.
Enrollment assistants ease site burden and increase patient engagement. Following are answers to five common questions about the use of this on-the-ground recruitment support.
Sponsors and CROs make increasing use of expert committees. Learn from members themselves on what it takes to have successful expert committee.
The WIRB-Copernicus Group’s (WCG) Clinical Services Division announced the acquisition of PharmaSeek, LLC, including its wholly-owned subsidiaries PFS Clinical and PatientWise, leading providers of turn-key administrative, consulting, patient recruitment and training solutions for clinical research sites.
Clinical research is complicated. At WCG, we frequently get questions about the ethical conduct of research from clinical team members at biopharma companies and study sites. We know that for many of the questions we get, the person asking is not the only one struggling with that issue. Read the questions your peers are asking – and if you don’t see yours, submit one of your own.
Small and emerging biopharma companies are conducting almost 50% of the clinical trials in the United States today. Unlike “big pharma”, small companies are usually working with lean teams, limited resources, and minimal infrastructure. In this paper, we explore some of the unique challenges for clinical development teams, and solutions that can reduce the pressure on teams and timelines.
New research on how people make decisions about research participation, and new approaches to the question of payments and compensation to participants, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.
Approximately 20% of cancer clinical trials will never be completed, because they fail to enroll enough participants to be able to answer the research question. Read this white paper to learn the impact that participant payments may play on clinical trial recruitment.
